Rallybio Corporation (RLYB)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 1 | 1 | 1 | - |
| Operating profit | $m | -28 | -24 | ||||||
| Net profit | $m | -26 | -47 | -67 | -75 | -58 | -9 | - | -31 |
| EPS reported | $ | -1.59 | 7.99 | ||||||
| Operating cashflow per share | $ | -5.30 | 4.62 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -5.30 | 4.62 | ||||||
| Free cash flow | $m | -30 | 26 | ||||||
| Net debt | $m | -55 | -93 | ||||||
| Book value equity | $m | 58 | 94 | ||||||
| Book value per share | $ | 10.30 | 16.30 | ||||||
| Number of shares | m | 5.63 | 5.8 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | 0.62 | ||||||
| P/B LTM | x | 0.53 | 0.33 | ||||||
| P/S LTM | x | 36.02 | 47.84 | ||||||
| P/FCF LTM | x | -1.04 | 1.17 | ||||||
| EV/EBITDA LTM | x | 0.01 | -0.01 | ||||||
| EV/Sales LTM | x | -0.34 | -4.16 | ||||||
| Earnings Yield LTM | % | -29.05% | +161.29% | ||||||
| FCF Yield | % | -96.47% | +85.23% | ||||||
| Quality | |||||||||
| ROE | % | -15.49% | +68.56% | ||||||
| ROIC | % | -48.28% | -24.40% | ||||||
| Operating margin | % | -32.71% | -36.72% | ||||||
| Gross margin | % | +89.28% | -11.08% | ||||||
| FCF/Sales | % | -3474.7% | +4077.4% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +34.91% | +1.57% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -169.39 | - | ||||||
| Net Debt/EBITDA | x | 1.12 | -3.44 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.94 | -0.98 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free